Patents for A61P 35 - Antineoplastic agents (221,099)
08/2009
08/20/2009WO2009004146A3 Novel herbimycin a analogue derivatives, compositions containing same and use thereof
08/20/2009US20090210954 Genes
08/20/2009US20090209747 Method to inhibit cell growth using oligonucleotides
08/20/2009US20090209734 Peptidyl prodrugs and linkers and stabilizers useful therefor
08/20/2009US20090209729 Recombinant chemokine-antigen vaccine
08/20/2009US20090209658 Embolic compositions
08/20/2009US20090209655 Isoflavone metabolites
08/20/2009US20090209648 Phenylacetic Acid Derivatives
08/20/2009US20090209641 Pharmaceutical composition for administration by injection
08/20/2009US20090209629 Nucleic Acid Functionalized Nanoparticles for Therapeutic Applications
08/20/2009US20090209606 Cancer Treatments
08/20/2009US20090209596 Oxazole Hydroxamic Acid Derivatives and Use Thereof
08/20/2009US20090209595 Method of treating of demyelinating diseases or conditions
08/20/2009US20090209594 Method of treating of demyelinating diseases or conditions
08/20/2009US20090209570 6-Aminomorphinane Derivatives, Method for the Production and Use Thereof
08/20/2009US20090209568 Spiro [Benzopyran] or Spiro [Benzofuran] Derivatives Which Inhibit the Sigma Receptor
08/20/2009US20090209566 Spirocyclic Compounds
08/20/2009US20090209559 Pharmaceutical compounds
08/20/2009US20090209555 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
08/20/2009US20090209554 Thiazoliums as transketolase inhibitors
08/20/2009US20090209537 Aurora inhibitors
08/20/2009US20090209534 Novel compounds and use of tetrahydropyridopyridothiophenes
08/20/2009US20090209530 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
08/20/2009US20090209523 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp)
08/20/2009US20090209522 Heterocyclic Non-Peptide GNRH Antagonists
08/20/2009US20090209521 Inhibition of VEGF Translation
08/20/2009US20090209520 2 -oxybenzamide derivatives as parp inhibitors
08/20/2009US20090209508 Compounds for Photochemotherapy
08/20/2009US20090209507 15-O-Desmethylmacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
08/20/2009US20090209496 Methods and compositions for enhancing the efficacy of rtk inhibitors
08/20/2009US20090209495 Use of edg receptor binding agents in cancer
08/20/2009US20090209493 Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
08/20/2009US20090209489 Compositions for the treatment of diabetis, system PH disorders, high blood pressure, and a cancer marker system
08/20/2009US20090209485 Modulating angiogenesis with nod factors such as glucosamine oligosaccharides
08/20/2009US20090209482 Azacytidine analogues and uses thereof
08/20/2009US20090209477 Azacytidine analogues and uses thereof
08/20/2009US20090209475 Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same
08/20/2009US20090209466 Peptides with anti-proliferative activity
08/20/2009US20090209450 MicroRNA Fingerprints During Human Megakaryocytopoiesis
08/20/2009US20090209037 Viral core protein-cationic lipid-nucleic acid-delivery complexes
08/20/2009US20090209034 Tumour rejection antigens
08/20/2009US20090209006 Taci-immunoglobulin fusion proteins
08/20/2009US20090208972 Cytotoxic protein and utlization thereof
08/20/2009US20090208969 Polynucleotides and Polypeptides Encoding Receptors
08/20/2009US20090208597 Heat processed vegetabilic fiber preparation and its use as inhibitor of the effects of carcinogenic substances in humans or animals
08/20/2009US20090208590 Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof
08/20/2009US20090208580 Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles
08/20/2009US20090208537 Anti-Neovasculature Preparations for Cancer
08/20/2009US20090208534 Attenuated salmonella as a delivery system for sirna-based tumor therapy
08/20/2009US20090208524 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
08/20/2009US20090208518 Immunogenic peptides for the treatment of prostate and breast cancer
08/20/2009US20090208514 Method of diagnosing esophageal cancer
08/20/2009US20090208505 Mutations of the pik3ca gene in human cancers
08/20/2009US20090208504 Polypeptides involved in immune response
08/20/2009US20090208500 Method of producing antibodies with improved function
08/20/2009US20090208498 Genetic Products Differentially Expressed In Tumors And The Use Thereof
08/20/2009US20090208493 Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors
08/20/2009US20090208489 Antibodies That Bind OV064 and Methods of Use Therefor
08/20/2009US20090208486 Pharmaceutical composition comprising cxcr3 inhibitor
08/20/2009US20090208476 Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins
08/20/2009US20090208475 Mina53 assays
08/20/2009US20090208468 SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
08/20/2009US20090208466 Ink-jet printing of tissues
08/20/2009US20090208431 preparing a non-staining mixture by mixing a turmeric extract with an acidity berry extract in a ratio from 1:1 parts to 1:20 parts (v/v); for cosmetic, protective, and healing purposes without staining skin or clothing yellow
08/20/2009US20090208416 Monoclonal antibodies against nkg2a
08/20/2009US20090208411 Cytotoxicity mediation of cells evidencing surface expression of CD44
08/20/2009US20090208410 Ed-b fibronectin as stratification marker for anti-tumor drugs
08/20/2009DE10329874B4 Tajixanthonhydrat und dessen Verwendung zur Behandlung von Tumorerkrankungen Tajixanthonhydrat and its use for the treatment of tumor diseases
08/20/2009DE102008010363A1 Sgk1 als therapeutisches und diagnostisches Target für karzinomatöse Erkrankungen Sgk1 as therapeutic and diagnostic target for cancerous diseases
08/20/2009DE102008009609A1 Substituierte 4-(Indol-3-yl)chinazoline und deren Verwendung und Herstellung Substituted 4- (indol-3-yl) quinazolines and their use and production
08/20/2009CA2747133A1 Uses of modified elr-cxc chemokine g31p
08/20/2009CA2715658A1 Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
08/20/2009CA2715460A1 Continuous cell programming devices
08/20/2009CA2715326A1 Doxorubicin adjuvants to reduce toxicity and methods for using the same
08/20/2009CA2715294A1 Genetic regulation of host defense mechanisms by mucosal exposure to natural interferon alpha species
08/20/2009CA2715293A1 Selective agonist of toll-like receptor 3
08/20/2009CA2714657A1 Anti-adam-15 antibodies and utilization of the same
08/20/2009CA2714445A1 Treatment of metastatic stage prostate cancer with degarelix
08/20/2009CA2714444A1 Method of treating prostate cancer with the gnrh antagonist degarelix
08/20/2009CA2714087A1 Inhibitors of checkpoint kinases
08/20/2009CA2713112A1 Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
08/19/2009EP2090656A1 Mutant androgen receptor, cancer cells expressing the same, method of constructing the same and use thereof
08/19/2009EP2090654A1 PARTIAL FRAGMENT OF REIC/Dkk-3 GENE AND THERAPEUTIC AGENT FOR CANCER CONTAINING THE SAME
08/19/2009EP2090589A1 Albumin-fused Kunitz domain peptides
08/19/2009EP2090585A1 Antigenic polypeptide usable as therapeutic agent for malignant neoplasm
08/19/2009EP2090577A2 Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
08/19/2009EP2090575A1 Processes and intermediates for the preparation of N4-phenyl-quinazoline-4-amine derivatives
08/19/2009EP2090571A1 Pyrimidine derivates, medicaments comprising them, their use and process of their preparation
08/19/2009EP2090322A1 Use of fsh receptor ligands for diagnosis and therapy of cancer
08/19/2009EP2090306A1 Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
08/19/2009EP2090305A1 Liposome encapsulating ammine-platinum complex at high concentration, and method for production of the liposome
08/19/2009EP2090304A2 Use of sugar phosphates, sugar phosphate analogues, amino acids and/or amino acid analogues for modulating the glycose-enzyme complex, the malate aspartate shuttle and/or transaminases
08/19/2009EP2090177A1 Food products having enhanced cocoa polyphenol content
08/19/2009EP2089514A1 Cancerous disease modifying antibodies
08/19/2009EP2089433A2 Therapy targeting cathepsin s
08/19/2009EP2089423A1 Antigen specific multi epitope vaccines
08/19/2009EP2089416A1 Depsipeptides and their therapeutic use
08/19/2009EP2089415A1 Depsipeptides and their therapeutic use
08/19/2009EP2089409A1 Compound having inhibitory activity on a rho-gtpase cell protein, a process for obtaining the same, pharmaceutical compositions comprision thereof and a method for the treatment of a rho-gtpase cell protein-mediated condition
08/19/2009EP2089404A1 Crystalline forms of zoledronic acid